DE3926606A1
(de)
|
1989-08-11 |
1991-02-14 |
Hoechst Ag |
Verfahren zur behandlung der cardialen sowie der vasculaeren hypertrophie und hyperplasie
|
DE4130514A1
(de)
|
1991-09-13 |
1993-03-18 |
Chemie Linz Deutschland |
Verfahren zur herstellung reiner n,n'-unsymmetrisch substituierter phenylharnstoffe
|
US5532243A
(en)
|
1992-02-14 |
1996-07-02 |
The Dupont Merck Pharmaceutical Company |
Antipsychotic nitrogen-containing bicyclic compounds
|
US5312814A
(en)
|
1992-12-09 |
1994-05-17 |
Bristol-Myers Squibb Co. |
α-phosphonocarboxylate squalene synthetase inhibitors
|
DE4341403A1
(de)
|
1993-12-04 |
1995-06-08 |
Basf Ag |
N-substituierte 3-Azabicycloalkan-Derivate, ihre Herstellung und Verwendung
|
US5523430A
(en)
|
1994-04-14 |
1996-06-04 |
Bristol-Myers Squibb Company |
Protein farnesyl transferase inhibitors
|
US5837716A
(en)
|
1995-11-13 |
1998-11-17 |
Albany Medical College |
Analgesic heterocyclic compounds
|
EP0944388A4
(fr)
|
1996-04-03 |
2001-08-16 |
Merck & Co Inc |
Inhibiteurs de la farnesyl-proteine transferase
|
NZ337515A
(en)
|
1997-03-03 |
2002-07-26 |
Eisai Co Ltd |
Use of cholinesterase inhibitors to treat disorders of attention
|
UA59433C2
(uk)
|
1998-01-27 |
2003-09-15 |
Авентіс Фармасьютікалс Продактс Інк. |
ЗАМІЩЕНІ ОКСОАЗАГЕТЕРОЦИКЛІЧНІ ІНГІБІТОРИ ФАКТОРА Хa ТА ПРОМІЖНІ СПОЛУКИ ДЛЯ ЇХ ОТРИМАННЯ
|
AU4692399A
(en)
|
1998-06-17 |
2000-01-05 |
Du Pont Pharmaceuticals Company |
Cyclic hydroxamic acids as metalloproteinase inhibitors
|
CA2346006A1
(fr)
|
1998-10-09 |
2000-04-20 |
Merck & Co., Inc. |
Desaturase d'acide gras delta 6
|
WO2000042852A1
(fr)
|
1999-01-25 |
2000-07-27 |
Smithkline Beecham Corporation |
Composes et procedes
|
CA2369822A1
(fr)
|
1999-04-14 |
2000-10-19 |
Merck & Co., Inc. |
Nouveau canal potassique humain potentiel-dependant
|
EP1190710A4
(fr)
|
1999-05-13 |
2003-04-02 |
Shionogi & Co |
Principes actifs destines au soin ou a la prevention de diabetes
|
EP1185508A2
(fr)
|
1999-05-24 |
2002-03-13 |
Cor Therapeutics, Inc. |
Inhibiteurs du facteur xa
|
BR0013179A
(pt)
|
1999-07-28 |
2002-04-02 |
Aventis Pharm Prod Inc |
Compostos de oxoazaeterociclila substituìda
|
US6372793B1
(en)
|
1999-08-20 |
2002-04-16 |
Florida Agricultural & Mechanical University |
Method for treatment of a neurological disease characterized by impaired neuromodulator function
|
MY125533A
(en)
*
|
1999-12-06 |
2006-08-30 |
Bristol Myers Squibb Co |
Heterocyclic dihydropyrimidine compounds
|
WO2001066114A1
(fr)
|
2000-03-03 |
2001-09-13 |
Eisai Co., Ltd. |
Nouvelles methodes reposant sur l'utilisation d'inhibiteurs de cholinesterase
|
US20020045613A1
(en)
|
2000-04-27 |
2002-04-18 |
Heinz Pauls |
1-aroyl-piperidinyl benzamidines
|
CA2409705A1
(fr)
|
2000-05-16 |
2001-11-22 |
Merck & Co., Inc. |
Gene responsable de la dystrophie maculaire dominante de stargardt
|
WO2002005819A1
(fr)
|
2000-07-15 |
2002-01-24 |
Smithkline Beecham Corporation |
Composes et procedes
|
US6962936B2
(en)
|
2001-04-27 |
2005-11-08 |
Vertex Pharmaceuticals Incorporated |
Triazole-derived kinase inhibitors and uses thereof
|
EP1406900B1
(fr)
|
2001-07-06 |
2006-10-04 |
Neurosearch A/S |
Nouveaux composes, preparation et utilisation de ces derniers
|
WO2003024456A1
(fr)
|
2001-09-20 |
2003-03-27 |
Eisai Co., Ltd. |
Methodes de traitement et de prevention des migraines
|
WO2003024450A1
(fr)
|
2001-09-20 |
2003-03-27 |
Eisai Co., Ltd. |
Methodes de traitement des maladies a prions
|
AU2002340232A1
(en)
|
2001-10-17 |
2003-04-28 |
Eisai Co., Ltd. |
Methods for treating substance abuse with cholinesterase inhibitors
|
DE60327922D1
(de)
|
2002-02-05 |
2009-07-23 |
Lilly Co Eli |
Harnstoff-linker verbindungen und ihre verwendung als ppar regulatoren
|
US20030195192A1
(en)
|
2002-04-05 |
2003-10-16 |
Fortuna Haviv |
Nicotinamides having antiangiogenic activity
|
KR20040090979A
(ko)
|
2002-03-13 |
2004-10-27 |
얀센 파마슈티카 엔.브이. |
히스톤 데아세틸레이즈의 신규한 억제제
|
AU2003228796A1
(en)
|
2002-05-01 |
2003-11-17 |
Eisai Co., Ltd. |
Cholinesterase inhibitors to prevent injuries caused by chemicals
|
WO2004034963A2
(fr)
|
2002-05-17 |
2004-04-29 |
Eisai Co., Ltd. |
Methodes et compositions utilisant des inhibiteurs de la cholinesterase
|
WO2004002531A1
(fr)
|
2002-06-26 |
2004-01-08 |
Ono Pharmaceutical Co., Ltd. |
Remedes pour les maladies provoquees par la contraction ou la dilatation vasculaire
|
MXPA05000947A
(es)
|
2002-07-25 |
2005-05-16 |
Pharmacia Italia Spa |
Biciclo-pirazoles activos como inhibidores de cinasa, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
|
AU2003256922A1
(en)
|
2002-07-31 |
2004-02-16 |
Smithkline Beecham Corporation |
Substituted heterocyclic compounds as modulators of the ccr5 receptor
|
WO2004017950A2
(fr)
|
2002-08-22 |
2004-03-04 |
Piramed Limited |
Inhibiteurs de phosphatidylinositol 3,5-biphosphate en tant qu'agents antiviraux
|
US7196082B2
(en)
|
2002-11-08 |
2007-03-27 |
Merck & Co. Inc. |
Ophthalmic compositions for treating ocular hypertension
|
WO2004089416A2
(fr)
|
2003-04-11 |
2004-10-21 |
Novo Nordisk A/S |
Polytherapie utilisant un inhibiteur de type 1 de la 11beta-hydroxysteroide deshydrogenase et un agent hypotenseur dans le traitement du syndrome metabolique et des troubles et maladies associes
|
US7501405B2
(en)
*
|
2003-04-11 |
2009-03-10 |
High Point Pharmaceuticals, Llc |
Combination therapy using an 11β-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent for the treatment of metabolic syndrome and related diseases and disorders
|
US7700583B2
(en)
*
|
2003-04-11 |
2010-04-20 |
High Point Pharmaceuticals, Llc |
11β-hydroxysteroid dehydrogenase type 1 active compounds
|
US20060287394A1
(en)
|
2003-05-30 |
2006-12-21 |
Konstantin Petrukhin |
Composition and method for treating macular disorders
|
MXPA05013770A
(es)
|
2003-06-19 |
2006-03-08 |
Pfizer Prod Inc |
Antagonista de neuroquinina 1.
|
AR045037A1
(es)
*
|
2003-07-10 |
2005-10-12 |
Aventis Pharma Sa |
Tetrahidro-1h-pirazolo [3,4-c] piridinas sustituidas, composiciones que las contienen y su utilizacion.
|
FR2857363B1
(fr)
*
|
2003-07-10 |
2007-09-07 |
Aventis Pharma Sa |
4,5,6,7-tetrahydro-1h-pyrazolo[3,4-c] pyridines substituees compositions les contenant et utilisation
|
WO2005074535A2
(fr)
|
2004-01-30 |
2005-08-18 |
Eisai Co., Ltd. |
Inhibiteurs de cholinesterase pour des troubles de la colonne vertebrale
|
US7435831B2
(en)
|
2004-03-03 |
2008-10-14 |
Chemocentryx, Inc. |
Bicyclic and bridged nitrogen heterocycles
|
EP1729761A4
(fr)
|
2004-03-05 |
2008-09-03 |
Eisai Co Ltd |
Traitement de cadasil avec des inhibiteurs de la cholinesterase
|
KR100907354B1
(ko)
|
2004-05-18 |
2009-07-10 |
쉐링 코포레이션 |
Pde4 억제제로서 유용한 치환된 2-퀴놀릴-옥사졸
|
FR2872416B1
(fr)
|
2004-07-01 |
2006-09-22 |
Oreal |
Utilisation de derives de piperidine pour lutter contre les rides
|
JPWO2006004201A1
(ja)
|
2004-07-01 |
2008-04-24 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
神経再生促進剤
|
EP1778685B1
(fr)
|
2004-08-02 |
2008-03-26 |
Schwarz Pharma Ag |
Carboxamides d'indolizine et leurs aza- et diaza-derives
|
JP2006077006A
(ja)
|
2004-08-13 |
2006-03-23 |
Eisai Co Ltd |
加齢に伴う過活動膀胱治療薬
|
JP2008515778A
(ja)
|
2004-08-18 |
2008-05-15 |
シリオン セラピューティクス, インコーポレイテッド |
眼の状態を13−シス−レチニル誘導体で処置するための組み合わせ方法、組成物および治療
|
JP4639696B2
(ja)
|
2004-08-31 |
2011-02-23 |
Jsr株式会社 |
磁性体複合粒子およびその製造方法
|
CN101084207A
(zh)
|
2004-09-20 |
2007-12-05 |
泽农医药公司 |
杂环衍生物及其作为硬脂酰CoA去饱和酶抑制剂的用途
|
DE602005025924D1
(en)
|
2004-09-20 |
2011-02-24 |
Xenon Pharmaceuticals Inc |
Royl-coa-desaturase
|
ATE495742T1
(de)
|
2004-10-27 |
2011-02-15 |
Janssen Pharmaceutica Nv |
Tetrahydro pyridinyl pyrazole cannabinoid modulatoren
|
JP2008519054A
(ja)
|
2004-11-04 |
2008-06-05 |
シリオン セラピューティクス, インコーポレイテッド |
レチノール−レチノール結合タンパク質(rbp)−トランスチレチン(ttr)複合体の形成のモジュレーター
|
WO2006058088A2
(fr)
|
2004-11-23 |
2006-06-01 |
Ptc Therapeutics, Inc. |
Derives de carbazole, de carboline et d'indole utilises dans l'inhibition de la production de vegf
|
JP2006176503A
(ja)
|
2004-11-26 |
2006-07-06 |
Tohoku Univ |
脳血管障害を伴うアルツハイマー病治療薬
|
BRPI0518616A
(pt)
|
2004-12-08 |
2008-01-15 |
Sirion Therapeutics Inc |
métodos para tratar doenças relacionadas com retinol, degeneração ou distrofia macular e diabetes tipo i ou tipo ii
|
US20080039442A1
(en)
*
|
2004-12-21 |
2008-02-14 |
Devgen Nv |
Compounds With Kv4 Ion Channel Activity
|
GB0503056D0
(en)
|
2005-02-14 |
2005-03-23 |
Smithkline Beecham Corp |
Chemical compounds
|
AU2006218403A1
(en)
|
2005-03-03 |
2006-09-08 |
Sirtris Pharmaceuticals, Inc. |
Fused heterocyclic compounds and their use as sirtuin modulators
|
CN101233132A
(zh)
|
2005-05-09 |
2008-07-30 |
海德拉生物科学公司 |
调节trpv3功能的化合物
|
US7632837B2
(en)
|
2005-06-17 |
2009-12-15 |
Bristol-Myers Squibb Company |
Bicyclic heterocycles as cannabinoid-1 receptor modulators
|
UA81382C2
(en)
|
2005-07-11 |
2007-12-25 |
|
Composition for treating retinol-related diseases by modulation of retinol binding
|
RU2422442C2
(ru)
*
|
2005-07-29 |
2011-06-27 |
Ф. Хоффманн-Ля Рош Аг |
Производные индол-3-ил-карбонил-пиперидина и пиперазина
|
CA2618653A1
(fr)
|
2005-08-12 |
2007-02-22 |
Takeda Pharmaceutical Company Limited |
Agent protegeant des cellules du cerveau/neuronales et agent therapeutique pour des troubles du sommeil
|
CA2620570A1
(fr)
|
2005-08-29 |
2007-03-08 |
Merck & Co., Inc. |
Agonistes des recepteurs de l'acide nicotinique, compositions contenant ces composes et methodes de traitement
|
AU2006296004B2
(en)
|
2005-09-27 |
2011-11-17 |
Shionogi & Co., Ltd. |
Sulfonamide derivative having PGD2 receptor antagonistic activity
|
WO2007044885A2
(fr)
|
2005-10-11 |
2007-04-19 |
Chemocentryx, Inc. |
Derives de piperidine et leurs procedes d'utilisation
|
DE102005049954A1
(de)
*
|
2005-10-19 |
2007-05-31 |
Sanofi-Aventis Deutschland Gmbh |
Triazolopyridin-derivate als Inhibitoren von Lipasen und Phospholipasen
|
US8168783B2
(en)
|
2005-11-18 |
2012-05-01 |
Ono Pharmaceutical Co., Ltd. |
Chemokine receptor antagonists and use thereof
|
WO2007086584A1
(fr)
|
2006-01-30 |
2007-08-02 |
Meiji Seika Kaisha, Ltd. |
NOUVEL INHIBITEUR DE FabK ET DE FabI/K
|
US20070254911A1
(en)
|
2006-03-27 |
2007-11-01 |
Mingde Xia |
Tetrahydro-Pyrazolo[3,4-c]Pyridine Cannabinoid Modulators
|
US20090275619A1
(en)
|
2006-04-03 |
2009-11-05 |
BOUERES Julia |
Amide Substituted Indazole and Benzotriazole Derivatives as Poly(ADP-Ribose)Polymerase (PARP) Inhibitors
|
ES2350013T3
(es)
|
2006-05-18 |
2011-01-14 |
F. Hoffmann-La Roche Ag |
Derivados de tiazolo-pirimidina/piridina-urea como antagonistas de receptor de adenosina a2b.
|
AU2007307031B2
(en)
|
2006-10-11 |
2011-11-24 |
Amgen Inc. |
Imidazo- and triazolo-pyridine compounds and methods of use therof
|
EP2102186B1
(fr)
|
2006-12-08 |
2011-10-05 |
F. Hoffmann-La Roche AG |
Indoles
|
DE102006060598A1
(de)
|
2006-12-21 |
2008-06-26 |
Merck Patent Gmbh |
Tetrahydrobenzoisoxazole
|
US8609840B2
(en)
|
2007-06-21 |
2013-12-17 |
Neuronascent, Inc. |
Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration using isothiazolopyrimidinones
|
US20090176778A1
(en)
|
2007-08-10 |
2009-07-09 |
Franz Ulrich Schmitz |
Certain nitrogen containing bicyclic chemical entities for treating viral infections
|
AU2008305303A1
(en)
|
2007-09-27 |
2009-04-02 |
Revision Therapeutics, Inc. |
Methods and compounds for treating retinol-related diseases
|
US7973079B2
(en)
|
2007-09-27 |
2011-07-05 |
Revision Therapeutics, Inc. |
Methods and compounds for treating retinol-related diseases
|
WO2009051244A1
(fr)
|
2007-10-18 |
2009-04-23 |
Takeda Pharmaceutical Company Limited |
Composé hétérocyclique
|
EP2085398A1
(fr)
|
2008-02-01 |
2009-08-05 |
Merz Pharma GmbH & Co. KGaA |
Pyrazolopyrimidines, leur procédé de préparation et leur utilisation en tant que médicament
|
WO2009145286A1
(fr)
|
2008-05-30 |
2009-12-03 |
武田薬品工業株式会社 |
Composé hétérocyclique
|
WO2010030757A2
(fr)
|
2008-09-10 |
2010-03-18 |
Kalypsys Inc. |
Inhibiteurs aminopyrimidine des récepteurs de l'histamine destinés au traitement d'une maladie
|
US20100168080A1
(en)
|
2008-12-17 |
2010-07-01 |
Khamrai Uttam |
Novel compounds useful as cc chemokine receptor ligands
|
CN102282147B
(zh)
|
2009-01-28 |
2015-09-30 |
卡拉治疗学股份有限公司 |
二环吡唑并-杂环
|
US20100204265A1
(en)
|
2009-02-09 |
2010-08-12 |
Genelabs Technologies, Inc. |
Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections
|
EP2404902A1
(fr)
*
|
2009-03-05 |
2012-01-11 |
Shionogi&Co., Ltd. |
Dérivés de la pipéridine et de la pyrrolidine dotés d'un antagonisme pour les récepteurs npy y5
|
TW201041868A
(en)
|
2009-03-20 |
2010-12-01 |
Intervet Int Bv |
Anthelmintic agents and their use
|
US20120010186A1
(en)
|
2009-03-23 |
2012-01-12 |
Merck Frosst Canada Ltd. |
Heterocyclic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase
|
US20120077854A1
(en)
|
2009-04-13 |
2012-03-29 |
Irm Llc |
Compositions and methods for modulating retinol binding to retinol binding protein 4 (rbp4)
|
RU2011146363A
(ru)
|
2009-04-16 |
2013-05-27 |
Такеда Фармасьютикал Компани Лимитед |
Производные n-ацил-n-фенилпиперазина, используемые (кроме того) для профилактики или лечения диабета
|
BRPI1010896A2
(pt)
|
2009-05-26 |
2019-09-24 |
Exelixis Inc |
benzoxazepinas como inibidores de pi3k/mtor e métodos de seus usos e fabricação
|
US8102887B2
(en)
|
2009-05-26 |
2012-01-24 |
Corning Incorporated |
Edge bonded optical packages
|
WO2010137738A1
(fr)
|
2009-05-28 |
2010-12-02 |
Otsuka Pharmaceutical Co., Ltd. |
Composés hétérocycliques pour le traitement d'états liés au stress
|
DK2477983T3
(en)
|
2009-09-16 |
2015-06-29 |
Univ Edinburgh |
(4-phenyl-piperidin-1-yl) - [5-1H-pyrazol-4-yl) -thiophene-3-yl] -METHANONFORBINDELSER AND THEIR USE
|
WO2011059881A1
(fr)
|
2009-11-12 |
2011-05-19 |
The Trustees Of Columbia University In The City Of New York |
Traitement de pathologies ophtalmiques avec des dérivés de fluorénone
|
WO2011072275A2
(fr)
|
2009-12-11 |
2011-06-16 |
Nono, Inc. |
Agents et méthodes de traitement de maladies ischémiques et d'autres maladies
|
WO2011109059A1
(fr)
|
2010-03-01 |
2011-09-09 |
Gtx, Inc. |
Composés destinés au traitement du cancer
|
WO2011116123A1
(fr)
|
2010-03-19 |
2011-09-22 |
Irm Llc |
Tafamidis pour le traitement de troubles ophtalmiques
|
US8748632B2
(en)
|
2010-03-19 |
2014-06-10 |
Sanford-Burnham Medical Research Institute |
Positive allosteric modulators of group II mGluRs
|
WO2011149993A2
(fr)
|
2010-05-25 |
2011-12-01 |
Abbott Laboratories |
Octahydrocyclopenta [c] pyrroles substitués utilisés en tant que modulateurs des canaux calciques
|
WO2011156632A2
(fr)
|
2010-06-09 |
2011-12-15 |
Georgetown University |
Compositions et procédés de traitement de tumeurs dans le système nerveux
|
CA2803009A1
(fr)
*
|
2010-07-01 |
2012-01-05 |
Amgen Inc. |
Composes heterocycliques et leur utilisation comme inhibiteurs de l'activite de pi3k
|
KR20140011301A
(ko)
|
2010-08-27 |
2014-01-28 |
노파르티스 아게 |
데아세틸라제의 히드록사메이트-기반 억제제
|
EP2642998B1
(fr)
|
2010-11-24 |
2020-09-16 |
The Trustees of Columbia University in the City of New York |
Antagoniste rbp4 non rétinoïde pour le traitement de la dégénérescence maculaire liée à l'âge et de la maladie de stargardt
|
EP2661265B1
(fr)
|
2010-12-23 |
2017-03-08 |
Merck Sharp & Dohme Corp. |
Quinoléines et aza-quinoléines en tant que modulateurs de l'activité du récepteur crth2
|
US9295676B2
(en)
|
2011-03-17 |
2016-03-29 |
The Trustees Of The University Of Pennsylvania |
Mutation mimicking compounds that bind to the kinase domain of EGFR
|
US9156830B2
(en)
|
2011-05-17 |
2015-10-13 |
Shionogi & Co., Ltd. |
Heterocyclic compounds
|
US9333202B2
(en)
|
2012-05-01 |
2016-05-10 |
The Trustees Of Columbia University In The City Of New York |
Non-retinoid antagonists for treatment of age-related macular degeneration and stargardt disease
|
WO2013166041A1
(fr)
|
2012-05-01 |
2013-11-07 |
The Trustees Of Columbia University In The City Of New York |
Ligands de la transthyrétine pouvant inhiber l'interaction de rbp4-ttr dépendante du rétinol pour le traitement de la dégénérescence maculaire liée à l'âge, de la maladie de stargardt et d'autres maladies de la rétine caractérisées par une accumulation excessive de lipofuscine
|
WO2013166040A1
(fr)
|
2012-05-01 |
2013-11-07 |
The Trustees Of Columbia University In The City Of New York |
S-fta et analogues de s-fta pouvant inhiber l'interaction de rbp4-ttr dépendante du rétinol pour le traitement de la dégénérescence maculaire liée à l'âge, de la maladie de stargardt et d'autres maladies de la rétine caractérisées par une accumulation excessive de lipofuscine
|
EP3378691A3
(fr)
|
2012-12-22 |
2018-11-21 |
Maytronics Ltd. |
Production d'électricité dans un robot pour piscines
|
TW201501713A
(zh)
*
|
2013-03-01 |
2015-01-16 |
Kyowa Hakko Kirin Co Ltd |
眼炎症性疾病之預防及/或治療劑
|
US9938291B2
(en)
|
2013-03-14 |
2018-04-10 |
The Trustess Of Columbia University In The City Of New York |
N-alkyl-2-phenoxyethanamines, their preparation and use
|
EP3495357B1
(fr)
*
|
2013-03-14 |
2021-05-05 |
The Trustees of Columbia University in the City of New York |
4-phénylpipéridines, leur préparation et leur utilisation
|
US9944644B2
(en)
|
2013-03-14 |
2018-04-17 |
The Trustees Of Columbia University In The City Of New York |
Octahydropyrrolopyrroles their preparation and use
|
EP2968303B1
(fr)
|
2013-03-14 |
2018-07-04 |
The Trustees of Columbia University in the City of New York |
Octahydrocyclopentapyrroles, leur préparation et leur utilisation
|
US20160030422A1
(en)
|
2013-03-14 |
2016-02-04 |
Konstantin Petrukhin |
Rbp4 antagonists for the treatment of age-related macular degeneration and stargardt disease
|
CA2947174C
(fr)
|
2014-04-30 |
2023-02-28 |
The Trustees Of Columbia University In The City Of New York |
4-phenylepiperidines substituees, leur preparation et utilisation
|